Stem Cell Therapeutics Adds Another U.S. Patent to Its Intellectual Property Portfolio

CALGARY, ALBERTA--(Marketwire - December 11, 2009) - Stem Cell Therapeutics Corp. (“SCT”) (TSX VENTURE: SSS) announced today that it has been granted U.S. Patent No. 7,629,169 entitled “Methods for the Production of Platelet-Derived Growth Factor-Responsive Neural Precursor Cells”. The claims cover methods of producing and self-renewing PDGF-responsive precursor (“PRP”) cells in culture using PDGF and FGF-2. This is the first patent to issue in this family.

Dr. Alan Moore, President and CEO, commented as follows:

“This patent is important to us because the technology allows for the production of large numbers of PRP cells, also known as oligodendrocyte progenitor cells, meaning it will be of particular interest as a therapy for a variety of neurodegenerative diseases such as multiple sclerosis, Parkinson’s disease and other chronic neurological diseases.”

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient’s own resident stem cells. The Company’s programs aim to repair brain and nerve function lost due to disease or injury. The Company’s extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington’s disease, Alzheimer’s disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.